Clinical series of PEL and extracavitary PEL
| . | El-Fattah71 . | Olszewski et al44 . | Guillet et al57 . | Boulanger et al55 . | Simonelli et al43 . | Chadburn et al7 . | Carbone et al6 . |
|---|---|---|---|---|---|---|---|
| No. of patients | 105 | 106 | 51 | 28 | 11 | 8 | 4 |
| Disease, n | |||||||
| PEL | 105 | 106 | 34 | 28 | 11 | — | — |
| Extracavitary PEL | — | — | 17 | — | — | 8 | 4 |
| Median age, y | 41 | 44 | 45 | 44 | 41 | 40 | 40 |
| Male, % | 90 | >95 | 92 | 96 | 90 | 100 | 75 |
| HIV+, % | NA | 100 | 100 | 100 | 100 | 100 | 75 |
| EBV coinfection, % | NA | NA | 66 | 72 | NA | NA | NA |
| History of KS, % | NA | NA | 49 | 67 | 27 | 25 | 25 |
| HAART, % | NA | NA | 69 | 78 | NA | 20 (1 of 5) | NA |
| Receiving chemotherapy, % | NA | 61 | 88 | 79 | 73 | 75 | 100 |
| CR rate, % | NA | NA | 56 | 41 | 42 | NA | NA |
| Median follow-up duration | 4 mo | NA | 10 y | 3.8 y | NA | 11 mo | 1.1 mo |
| Median OS | NA | 0.4 y | 10.2 mo | 6.2 mo | 6 mo | 11 mo | 0.8 mo |
| 1-y OS rate, % | 30 | NA | NA | 39.3 | NA | 40 | 0 |
| 3-y OS rate, % | 18 | NA | NA | NA | NA | 40 | 0 |
| 5-y OS rate, % | 17 | 28 | NA | NA | NA | 40 | 0 |
| . | El-Fattah71 . | Olszewski et al44 . | Guillet et al57 . | Boulanger et al55 . | Simonelli et al43 . | Chadburn et al7 . | Carbone et al6 . |
|---|---|---|---|---|---|---|---|
| No. of patients | 105 | 106 | 51 | 28 | 11 | 8 | 4 |
| Disease, n | |||||||
| PEL | 105 | 106 | 34 | 28 | 11 | — | — |
| Extracavitary PEL | — | — | 17 | — | — | 8 | 4 |
| Median age, y | 41 | 44 | 45 | 44 | 41 | 40 | 40 |
| Male, % | 90 | >95 | 92 | 96 | 90 | 100 | 75 |
| HIV+, % | NA | 100 | 100 | 100 | 100 | 100 | 75 |
| EBV coinfection, % | NA | NA | 66 | 72 | NA | NA | NA |
| History of KS, % | NA | NA | 49 | 67 | 27 | 25 | 25 |
| HAART, % | NA | NA | 69 | 78 | NA | 20 (1 of 5) | NA |
| Receiving chemotherapy, % | NA | 61 | 88 | 79 | 73 | 75 | 100 |
| CR rate, % | NA | NA | 56 | 41 | 42 | NA | NA |
| Median follow-up duration | 4 mo | NA | 10 y | 3.8 y | NA | 11 mo | 1.1 mo |
| Median OS | NA | 0.4 y | 10.2 mo | 6.2 mo | 6 mo | 11 mo | 0.8 mo |
| 1-y OS rate, % | 30 | NA | NA | 39.3 | NA | 40 | 0 |
| 3-y OS rate, % | 18 | NA | NA | NA | NA | 40 | 0 |
| 5-y OS rate, % | 17 | 28 | NA | NA | NA | 40 | 0 |
Dashes indicate that patients were not included.
CR, complete response; HAART, highly active antiretroviral therapy; NA, not available.